IP Library Granted Patent US 6,878,525
Granted Patent B1
US 6,878,525 · App. 09/979,603 · Granted Apr 12, 2005

Peptide leukotriene receptor

Assignees: Yamanouchi Pharmaceutical Co, Ltd.; Helix Research Institute
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,878,525
App. No.
09/979,603
Granted
Apr 12, 2005
Kind
B1
Abstract

A cDNA encoding a novel LTC 4 receptor has been isolated. Provision of the novel protein, an LTC 4 receptor, enabled binding experiments using the LTC 4 . By screening for compounds that modulate LTC 4 receptor activity based on these binding experiments, development of drugs targeting the LTC 4 receptor becomes possible.

Claims (24)

1. A purified mammalian protein with leukotriene C4 receptor activity selected from the group consisting of:

(a) a protein comprising an amino acid sequence of SEQ ID NO: 2, 18, or 22, and

(b) a protein comprising an amino acid sequence with at least 70% homology to SEQ ID NO: 2, 18, or 22.

2. A method for detecting the ability of a test compound to modulate leukotriene C4 receptor activity, comprising the steps of:

(a) contacting the test compound with a mammalian protein of claim 1 , or with transformed cells expressing a mammalian protein with leukotriene C4 receptor activity selected from the group consisting of:

(i) a mammalian protein comprising an amino acid sequence of SEQ ID NO: 2, 18, or 22, and

(ii) a mammalian protein comprising an amino acid sequence with at least 70% homology to SEQ ID NO: 2, 18, or 22, in the presence of a ligand for leukotriene C4 receptor, and

(b) measuring changes in leukotriene C4 receptor activity.

3. A method of screening for a compound which modulates leukotriene C4 receptor activity, comprising the steps of:

(a) contacting the test compound with a mammalian protein of claim 1 , or with transformed cells expressing a mammalian protein with leukotriene C4 receptor activity selected from the group consisting of:

(i) a mammalian protein comprising an amino acid sequence of SEQ ID NO: 2, 18, or 22, and

(ii) a mammalian protein comprising an amino acid sequence with at least 70% homology to SEQ ID NO: 2, 18, or 22, in the presence of a ligand for leukotriene C4 receptor,

(b) measuring changes in leukotriene C4 receptor activity, and

(c) selecting the compound that modulates leukotriene C4 receptor activity.

4. The purified mammalian protein of claim 1 , wherein in part (b) said protein comprises an amino acid sequence with at least 90% homology to SEQ ID NO: 2, 18, or 22.

5. An isolated DNA encoding a mammalian protein with leukotriene C4 receptor activity, said protein selected from the group consisting of:

(a) a protein comprising an amino acid sequence of SEQ ID NO: 2, 18, or 22, and

(b) a protein comprising an amino acid sequence with at least 70% homology to SEQ ID NO: 2, 18, or 22.

6. A transformant carrying the DNA of claim 5 in an expressible manner.

7. A method for producing a mammalian protein with leukotriene C4 receptor activity selected from the group consisting of:

(a) a mammalian protein comprising an amino acid sequence of SEQ ID NO: 2, 18, or 22, and

(b) a mammalian protein comprising an amino acid sequence with at least 70% homology to SEQ ID NO: 2, 18, or 22.

comprising the steps of culturing the transformant of claim 6 , and recovering the expressed product.

8. The isolated DNA of claim 5 , wherein in part (b) said protein comprises an amino acid sequence with at least 90% homology to SEQ ID NO: 2, 18, or 22.

Assignments (5)
MERGER Recorded Sep 22, 2005
From: YAMANOUCHI PHARMACEUTICAL CO., LTD.
To: ASTELLAS PHARMA INC.
Reel/Frame 016570/0324 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2003
From: HELIX RESEARCH INSTITUTE
To: YAMANOUCHI PHARMACEUTICAL CO., LTD.
Reel/Frame 014038/0772 →
CORRECTIVE ASSIGNMENT Recorded Jan 8, 2003
From: TAKASAKI, JUN; KAMOHARA, MASAZUMI; MATSUMOTO, MITSUYUKI; SAITO, TETSU; SUGIMOTO, TOHRU; OTA, TOSHIO; ISOGAI, TAKAO; NISHIKAWA, TETSUO; KAWAI, YURI
To: YAMANOUCHI PHARMACEUTICAL CO., LTD.; HELIX RESEARCH INSTITUTE
Reel/Frame 013644/0888 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2002
From: TAKASAKI, JUN; KAMOHARA, MASAZUMI; MATSUMOTO, MITSUYUKI; SAITO, TETSU; SUGIMOTO, TOHRU; OTA, TOSHIO; ISOGAI, TAKAO; NISHIKAWA, TETSUO; KAWAI, YURI
To: YAMANOUCHI PHARMACEUTICAL CO., LTD.; HELIX RESEARCH INSTITUTE
Reel/Frame 013229/0045 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2002
From: TAKASAKI, JUN; KAMOHARA, MASAZUMI; MATSUMOTO, MITSUYUKI; SAITO, TETSU; SUGIMOTO, TOHRU; OTA, TOSHIO; ISOGAI, TAKAO; NISHIKAWA, TETSUO; KAWAI, YURI
To: YAMANOUCHI PHARMACEUTICAL CO., LTD.; HELIX RESEARCH INSTITUTE
Reel/Frame 013320/0436 →
Priority Claims (1)
JP 11-259986 · Sep 14, 1999 · national